个人简介

2017年12月毕业于中国药科大学药理学专业获博士学位，2018年8月进入儿童医院保健科工作，现为研究实习员。本人研究生阶段主要从事消化道疾病（急、慢性溃疡性结肠炎）的治疗和炎症小体的调控机制相关研究工作，部分研究论文已经发表在Experimental Cell Research，Oncotarget，Biochemical Pharmacology，International Journal of Cancer，Antioxidants and Redox Signaling 等国际期刊上。目前，本人所在课题组致力于生命早期过度营养促进 NAFLD 等肥胖相关并发症发生发展的机制方面研究。

主持科研项目

1.叶绿醇通过干预脂肪代谢改善早期过度营养诱导的成年期肥胖的作用及机制研究（NMUB2018093），南京医科大学面上项目，2019.1-2021.12，3万

2.基于 CREB1/HtrA2/Hax-1 研究早期过度营养促进 NAFLD 发生发展的作用机制（81903338），国家自然科学基金青年项目，2020-2022，20万

代表性论文

1.Zhou, W#., Liu, X., Cheng, K., Zhang, X., Lu, J., and Hu, R*. X-11-5-27, a daidzein derivative, inhibits NLRP3 inflammasome activity via promoting autophagy. Experimental cell research, 2017; 360:320-327.

2.Zhou, W#., Liu, X., Zhang, X., Tang, J., Li, Z., Wang, Q.*, and Hu, R*. Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome. Oncotarget 2017; 8: 58903-58917.

3.Liu, X., Zhou, W., Zhang, X., Ding, Y., Du, Q., and Hu, R*. 1-L-MT, an IDO inhibitor, prevented colitis-associated cancer by inducing CDC20 inhibition-mediated mitotic death of colon cancer cells. International journal of cancer 2018;143:1516-1529.

4.Liu, X., Zhou, W., Zhang, X., Lu, P., Du, Q., Tao, L., Ding, Y., Wang, Y., and Hu, R*.  Dimethyl fumarate ameliorates dextran sulfate sodium-induced murine experimental colitis by activating Nrf2 and suppressing NLRP3 inflammasome activation. Biochemical pharmacology 2016;112, 37-49.

5.Zhang, X., Liu, X., Zhou, W., Yang, M., Ding, Y., Wang, Q., and Hu, R*. Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2. Cell death & disease 2018, 9:190.

6.Liu, X., Zhang, X., Ding, Y., Zhou, W., Tao, L., Lu, P., Wang, Y., and Hu, R*. Nuclear Factor E2-Related Factor-2 Negatively Regulates NLRP3 Inflammasome Activity by Inhibiting Reactive Oxygen Species-Induced NLRP3 Priming. Antioxidants & redox signaling 2017;26:28-43.

7.Wang, Y., Wang, H., Qian, C., Tang, J., Zhou, W., Liu, X., You, Q.*, and Hu, R*.3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(1 1bH)-one (compound 1), a novel potent Nrf2/ARE inducer, protects against DSS-induced colitis via inhibiting NLRP3 inflammasome. Biochemical pharmacology 2016; 101, 71-86.